Please wait while the formulary information is being retrieved.
BRUKINSA (zanubrutinib)
- Mantle cell lymphoma
80 mg capsule
- 2 capsules (160 mg) by oral route 2 times per day
Mantle cell lymphoma
- 1 capsule (80 mg) by oral route once daily
- 1 capsule (80 mg) by oral route 2 times per day
- 2 capsules (160 mg) by oral route 2 times per day
- 2 capsules (160 mg) by oral route once daily
- 4 capsules (320 mg) by oral route once daily
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Anemia
- Child-pugh class C hepatic impairment
- Increased risk of bleeding
- Neutropenic disorder
- Pregnancy
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- Atrial fibrillation
- Hypertension
BRUKINSA (zanubrutinib)
- Mantle cell lymphoma
- Anemia
- Hyperbilirubinemia
- Increased alanine transaminase
- Infection
- Leukopenia
- Lymphocytosis
- Neutropenic disorder
- Thrombocytopenic disorder
- Bruising
- Cough
- Diarrhea
- Skin rash
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Atrial fibrillation
- Atrial flutter
- Bacterial infection
- Gastrointestinal hemorrhage
- Hemorrhage
- Hypertension
- Hypokalemia
- Opportunistic fungal infection
- Opportunistic viral infection
- Pneumonia
- Squamous cell carcinoma of skin
- Basal cell carcinoma of skin
- Constipation
- Fatigue
- Hematuria
- Musculoskeletal pain
- Petechiae
- Purpura
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hemothorax
- Intracranial bleeding
- Reactivation of hepatitis B
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Zanubrutinib
Safety and efficacy not established in age < 18 years.
- 1 Day – 18 Years
- Safety and efficacy not established in age < 18 years.
Zanubrutinib
- Severity Level:
D
- Additional Notes: Based on animal data, fetal harm may occur, consider risk vs. benefit
Contraindicated
Zanubrutinib
None
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Zanubrutinib
Cardiovascular-Increased risk of atrial fibrillation and atrial flutter in patients with preexisting cardiac conditions or acute infection. Increased risk of bleeding while on zanubrutinib. Antiplatelet and anticoagulants may further increase risk of hemorrhage. General-In clinical trials, patients greater than 65 years of age experienced higher rates of Grade 3/4 adverse reactions compared to younger patients.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Mantle cell lymphoma | |
| C83.1 | Mantle cell lymphoma |
| C83.10 | Mantle cell lymphoma, unspecified site |
| C83.11 | Mantle cell lymphoma, lymph nodes of head, face, and neck |
| C83.12 | Mantle cell lymphoma, intrathoracic lymph nodes |
| C83.13 | Mantle cell lymphoma, intra-abdominal lymph nodes |
| C83.14 | Mantle cell lymphoma, lymph nodes of axilla and upper limb |
| C83.15 | Mantle cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.16 | Mantle cell lymphoma, intrapelvic lymph nodes |
| C83.17 | Mantle cell lymphoma, spleen |
| C83.18 | Mantle cell lymphoma, lymph nodes of multiple sites |
| C83.19 | Mantle cell lymphoma, extranodal and solid organ sites |
| 0-9 | A-Z |
|---|---|
| C83.1 | Mantle cell lymphoma |
| C83.10 | Mantle cell lymphoma, unspecified site |
| C83.11 | Mantle cell lymphoma, lymph nodes of head, face, and neck |
| C83.12 | Mantle cell lymphoma, intrathoracic lymph nodes |
| C83.13 | Mantle cell lymphoma, intra-abdominal lymph nodes |
| C83.14 | Mantle cell lymphoma, lymph nodes of axilla and upper limb |
| C83.15 | Mantle cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.16 | Mantle cell lymphoma, intrapelvic lymph nodes |
| C83.17 | Mantle cell lymphoma, spleen |
| C83.18 | Mantle cell lymphoma, lymph nodes of multiple sites |
| C83.19 | Mantle cell lymphoma, extranodal and solid organ sites |
Formulary Reference Tool